Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its pipeline includes drug candidates targeting obesity, NASH, lipid disorders, and rare genetic conditions like X-linked adrenoleukodystrophy. The company focuses on innovative receptor agonists, including GLP-1/GIP dual agonists and thyroid receptor beta agonists, with a business model centered on research, clinical development, licensing, and potential commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.